Company intelligence / Profile preview
Molecure
Warsaw, Polandmolecure.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Molecure has two clinical-stage programs: OATD-01 (Phase 2 for sarcoidosis) and OATD-02 (Phase 1 for cancer). The company started a Phase II trial for OATD-01 in sarcoidosis patients in March 2024. OATD-02 began Phase I clinical trials with first patient dosing in Q1 2023.
- Therapeutic areas
- PulmonologyMetabolic DisordersImmunologyOncologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Ocean Biomedical (NASDAQ: OCEA)
Beyond the preview
Go deeper on Molecure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecure.